Oral administration of interferon-α2b-transformed Bifidobacterium longum protects BALB/c mice against coxsackievirus B3-induced myocarditis

Virology Journal

Volumn 8, Issue , 2011, Pages

  Yu, Zhijian ^a   Huang, Zhen ^a   Shao, Chongwen ^b   Huang, Yuanjian ^b   Zhang, Fan ^a   Yang, Jin ^a   Deng, Lili ^a   Zeng, Zhongming ^a   Deng, Qiwen ^a   Zeng, Weiseng ^b  

^a Shenzhen Nanshan People s Hospital and the 6th Affiliated Hospital of Shenzhen University Medical School   (China)

^b SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

Bifidobacterium; Coxsackievirus B; Enterovirus; Interferon; Myocarditis; Oral administration

Indexed keywords

ALPHA2B INTERFERON;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIFIDOBACTERIUM LONGUM; COMPARATIVE STUDY; CONTROLLED STUDY; COXSACKIE VIRUS B3; DISEASE SEVERITY; HUMAN; MALE; MOUSE; MYOCARDITIS; NONHUMAN; TH1 CELL;

ANIMALS; BIFIDOBACTERIUM; COXSACKIEVIRUS INFECTIONS; ENTEROVIRUS; GENE TRANSFER TECHNIQUES; HUMANS; INTERFERON-ALPHA; INTESTINES; MALE; MICE; MICE, INBRED BALB C; MYOCARDITIS; POLYETHYLENE GLYCOLS; PROMOTER REGIONS, GENETIC; RECOMBINANT FUSION PROTEINS; RECOMBINANT PROTEINS; SPLEEN;

BIFIDOBACTERIUM; BIFIDOBACTERIUM LONGUM; COXSACKIEVIRUS; ENTEROVIRUS; HUMAN ENTEROVIRUS B; MUS;

EID: 84855309540     PISSN: None     EISSN: 1743422X     Source Type: Journal    
DOI: 10.1186/1743-422X-8-525     Document Type: Article

References (27)

1. Lack of efficacy of low dose oral interferon alfa in symptomatic HIV-1 infection: a randomised, double blind, placebo controlled trial. Katabira ET, Sewankambo NK, Mugerwa RD, Belsey EM, Mubiru FX, Othieno C, Kataaha P, Karam M, Youle M, Perriens JH, Lange JM, Sex Transm Infect 1998 74 4 265 270 10.1136/sti.74.4.265 9924466 (Pubitemid 28415202)
2. Oral use of interferon. Cummins J, Beilharz M, Krakowka S, J Interferon Cytokine Res 1999 19 853 857 10.1089/107999099313352 10476928 (Pubitemid 29406637)
3. Chronic major aphthous stomatitis: oral treatment with low-dose alpha-interferon. Hutchinson VA, Mok WL, Angenend JL, Cummins JM, Richards AB, Mol Biother 1990 2 4 217 220 2288721
4. A pilot double-blind, randomized, and placebo-controlled study of orally administered IFN - n1 (Ins) in pediatric patients with measles. Lecciones JA, Abejar NJ, Dimaano EE, Bartolome R, Cinco S, Mariano N, Yerro ME, Cobar S, Fuggan B, J Interferon Cytokine Res 1998 18 647 652 10.1089/jir.1998.18.647 9781802 (Pubitemid 28457996)
5. Biodegradable nanogels for oral delivery of interferon for norovirus infection. Kim Y, Thapa M, Hua DH, Chang KO, Antiviral Res 2011 89 2 165 173 10.1016/j.antiviral.2010.11.016 21144866
6. Use of oromucosally administered interferon-alpha in the prevention and treatment of animal diseases. Dec M, Puchalski A, Pol J Vet Sci 2008 11 175 186 18683548 (Pubitemid 351896353)
7. Bifidobacterium longum as a delivery system of TRAIL and endostatin cooperates with chemotherapeutic drugs to inhibit hypoxic tumor growth. Hu B, Kou L, Li C, Zhu LP, Fan YR, Wu ZW, Wang JJ, Xu GX, Cancer Gene Ther 2009 16 655 663 10.1038/cgt.2009.7 19229287
8. A novel binary expression vector for production of human IL-10 in Escherichia coli and Bifidobacterium longum. Reyes Escogido ML, De Leán Rodríguez A, Barba de la Rosa AP, Biotechnol Lett 2007 29 1249 1253 10.1007/s10529-007-9376-8 17487549 (Pubitemid 47035016)
9. Production of human basic fibroblast growth factor (FGF-2) in Bifidobacterium breve using a series of novel expression/secretion vectors. Shkoporov AN, Efimov BA, Khokhlova EV, Kafarskaia LI, Smeianov VV, Biotechnol Lett 2008 30 1983 1988 10.1007/s10529-008-9772-8 18575808
10. A novel Bifidobacterium infantis-mediated TK/GCV suicide gene therapy system exhibits antitumor activity in a rat model of bladder cancer. Tang W, He Y, Zhou S, Ma Y, Liu G, J Exp Clin Cancer Res 2009 28 155 10.1186/1756-9966-28- 155 20015348
11. Bifidobacterium longum as a delivery system for gene therapy of chemically induced rat mammary tumors. Yazawa K, Fujimori M, Nakamura T, Sasaki T, Amano J, Kano Y, Taniguchi S, Breast Cancer Res Treat 2001 66 165 170 10.1023/A:1010644217648 11437103 (Pubitemid 32521423)
12. Signal peptide of Arabinosidase enhances secretion of interferon-alpha2b protein by Bifidobacterium longum. Deng Q, Zeng W, Yu Z, Arch Microbiol 2009 191 681 686 10.1007/s00203-009-0496-5 19652954
13. Increased mRNA expression of interferon-induced Mx1 and immunomodulation following oral administration of IFN-2b-transformed B. longum to mice. Yu Z, Zeng Z, Huang Z, Lian J, Yang J, Deng Q, Zeng W, Arch Microbiol 2010 192 633 638 10.1007/s00203-010-0589-1 20535450
14. Inhibition of coxsackievirus B3 carrier state infection of cultured human myocardial fibroblasts by ribavirin and human natural interferon-alpha. Heim A, Grumbach I, Pring-Akerblom P, Stille-Siegener M, Muller G, Kandolf R, Figulla HR, Antivir Res 1997 34 101 111 10.1016/S0166-3542(97)01028-0 9191017 (Pubitemid 27220186)
15. Coxsackie B3 virus can replicate in cultured human fetal heart cells and is inhibited by interferon. Kandolf R, Canu A, Hofschneider PH, J Mol Cell Cardiol 1985 17 167 181 10.1016/S0022-2828(85)80019-5 3889351 (Pubitemid 16241101)
16. Combination treatment with ribavirin and interferon for coxsackievirus B3 replication. Okada I, Matsumori A, Matoba Y, Tominaga M, Yamada T, Kawai C, J Lab Clin Med 1992 120 569 573 1328433
17. The interferon inducer ampligen [poly(I)-poly(C12U)] markedly protects mice against coxsackie B3 virus-induced myocarditis. Padalko E, Nuyens D, De Palma A, Verbeken E, Aerts JL, De Clercq E, Carmeliet P, Neyts J, Antimicrob Agents Chemother 2004 48 1 267 274 10.1128/AAC.48.1.267-274.2004 14693549 (Pubitemid 38040207)
18. Protective role for interferon-beta in coxsackievirus B3 infection. Deonarain R, Cerullo D, Fuse K, Liu PP, Fish EN, Circulation 2004 110 3540 3543 10.1161/01.CIR.0000136824.73458.20 15249500 (Pubitemid 39612568)
19. Antiviral and myocyte protective effects of murine interferon-beta and -alpha2 in coxsackievirus B3-induced myocarditis and epicarditis in BALB/c mice. Wang YX, da Cunha V, Vincelette J, White K, Velichko S, Xu YF, Gross C, Fitch RM, Halks-Miller M, Larsen BR, Am J Physiol Heart Circ Physiol 2007 293 69 H76 10.1152/ajpheart.00154.2007 17434974 (Pubitemid 47105060)
20. Phyllaemblicin B inhibits coxsackie virus B3 induced apoptosis and myocarditis. Wang YF, Wang XY, Ren Z, Qian CW, Li YC, Kaio K, Wang QD, Zhang Y, Zheng LY, Jiang JH, Yang CR, Liu Q, Zhang YJ, Antiviral Res 2009 84 2 150 158 10.1016/j.antiviral.2009.08.004 19699238
21. Th17 cells contribute to viral replication in coxsackievirus B3-induced acute viral myocarditis. Yuan J, Yu M, Lin QW, Cao AL, Yu X, Dong JH, Wang JP, Zhang JH, Wang M, Guo HP, Cheng X, Liao YH, J Immunol 2010 185 7 4004 4010 10.4049/jimmunol.1001718 20802148
22. Orally administered OVA/CpG-ODN induces specific mucosal and systemic immune response in young and aged mice. Alignani D, Maletto B, Liscovsky M, Rápolo A, Morán G, Pistoresi-Palencia MC, J Leukocyte Biol 2005 77 898 905 10.1189/jlb.0604330 15758079 (Pubitemid 40770841)
23. Virus free, cell-based assay for the quantification of murine type I interferons. Bollati-Fogolín M, Müller W, J Immunol Methods 2005 306 169 175 10.1016/j.jim.2005.08.005 16209875 (Pubitemid 41739848)
24. Mx1 and IP-10: biomarkers to measure IFNbeta activity in mice following gene-based delivery. Petry H, Cashion L, Szymanski P, Ast O, Orme A, Gross C, Bauzon M, Brooks A, Schaefer C, Gibson H, Qian H, Rubanyi GM, Harkins RN, J Interferon Cytokine Res 2006 26 699 705 10.1089/jir.2006.26.699 17032164 (Pubitemid 44934109)
25. Acute viral myocarditis. Dennert R, Crijns HJ, Heymans S, Eur Heart J 2008 29 2073 2082 10.1093/eurheartj/ehn296 18617482
26. David RL, CRC Handbook of Chemistry and Physics Boca Raton: CRC Press 88 2007 110
27. Treatment of mice with dextran sulfate sodium-induced colitis with human interleukin 10 secreted by transformed Bifidobacterium longum. Yao J, Wang JY, Lai MG, Li YX, Zhu HM, Shi RY, Mo J, Xun AY, Jia CH, Feng JL, Wang LS, Zeng WS, Liu L, Mol Pharm 2011 8 2 488 497 10.1021/mp100331r 21271712